Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an update.
Chimeric Therapeutics Ltd. has announced a change in the interests of its substantial holder, Paul Hopper, as of July 25, 2025. The voting power associated with fully paid ordinary shares has decreased from 10.2% to 6.3%, indicating a significant shift in shareholder influence. This change may impact the company’s governance and decision-making processes, potentially affecting its strategic direction and stakeholder relationships.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of innovative cell therapies. The company is primarily engaged in creating advanced treatments for cancer, leveraging cutting-edge research and technology to improve patient outcomes.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.75M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.